210 related articles for article (PubMed ID: 2736308)
1. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
Anger B; Porzsolt F; Leichtle R; Heinze B; Bartram C; Heimpel H
Blut; 1989 Jun; 58(6):275-8. PubMed ID: 2736308
[TBL] [Abstract][Full Text] [Related]
2. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
Guilhot F; Dreyfus B; Desmarest MC; Giraud C; Huret JL; Brizard A; Tanzer J
Nouv Rev Fr Hematol (1978); 1989; 31(2):171-3. PubMed ID: 2771633
[TBL] [Abstract][Full Text] [Related]
3. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.
Silver RT; Woolf SH; Hehlmann R; Appelbaum FR; Anderson J; Bennett C; Goldman JM; Guilhot F; Kantarjian HM; Lichtin AE; Talpaz M; Tura S
Blood; 1999 Sep; 94(5):1517-36. PubMed ID: 10477676
[TBL] [Abstract][Full Text] [Related]
4. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM
Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778
[TBL] [Abstract][Full Text] [Related]
5. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
Higano CS; Chielens D; Raskind W; Bryant E; Flowers ME; Radich J; Clift R; Appelbaum F
Blood; 1997 Oct; 90(7):2549-54. PubMed ID: 9326220
[TBL] [Abstract][Full Text] [Related]
6. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
7. Leukocyte interferon in the treatment of chronic myelogenous leukemia in second chronic phase.
Wahlin A; Holm J; Engman K
Acta Oncol; 1991; 30(5):611-5. PubMed ID: 1892679
[TBL] [Abstract][Full Text] [Related]
8. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
[TBL] [Abstract][Full Text] [Related]
9. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b.
Bergsagel DE; Messner H
Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea versus interferon alfa-2b in chronic myelogenous leukaemia: preliminary results of an open French multicentre randomized study.
Broustet A; Reiffers J; Marit G; Fiere D; Jaubert J; Reynaud J; Pris J; Bernard P; Charrin C; Wen ZQ
Eur J Cancer; 1991; 27 Suppl 4():S18-21. PubMed ID: 1799467
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
Wadler S; Goldman M; Lyver A; Wiernik PH
Cancer Res; 1990 Apr; 50(7):2056-9. PubMed ID: 2317795
[TBL] [Abstract][Full Text] [Related]
12. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older.
Cortes J; Kantarjian H; O'Brien S; Robertson LE; Pierce S; Talpaz M
Am J Med; 1996 Apr; 100(4):452-5. PubMed ID: 8610733
[TBL] [Abstract][Full Text] [Related]
13. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. The Benelux CML Study Group.
Blood; 1998 Apr; 91(8):2713-21. PubMed ID: 9531580
[TBL] [Abstract][Full Text] [Related]
14. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.
Kantarjian HM; Smith TL; O'Brien S; Beran M; Pierce S; Talpaz M
Ann Intern Med; 1995 Feb; 122(4):254-61. PubMed ID: 7825760
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia.
Sacchi S; Kantarjian HM; O'Brien S; Beran M; Koller C; Pierce S; Kornblau S; Estey E; Keating MJ; Talpaz M
Leukemia; 1997 Oct; 11(10):1610-6. PubMed ID: 9324278
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
Nese M; de Bellis R; Urtiarte R; Di Landro J
Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
[TBL] [Abstract][Full Text] [Related]
17. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.
; Tura S; Baccarani M; Zuffa E; Russo D; Fanin R; Zaccaria A; Fiacchini M
N Engl J Med; 1994 Mar; 330(12):820-5. PubMed ID: 8114834
[TBL] [Abstract][Full Text] [Related]
18. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a.
Berman E; Heller G; Kempin S; Gee T; Tran LL; Clarkson B
Blood; 1990 Feb; 75(4):839-45. PubMed ID: 2302457
[TBL] [Abstract][Full Text] [Related]
19. The effects of interferon-alpha on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint.
Dowding C; Guo AP; Maisin D; Gordon MY; Goldman JM
Br J Haematol; 1991 Feb; 77(2):165-71. PubMed ID: 2004017
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
